Thromboembolic risk in patients with high titre anticardiolipin and multiple antiphospholipid antibodies
Summary Asymptomatic antiphospholipid antibody (aPL) carriers with high risk for thrombosis may benefit from preventive anticoagulation. It was our objective to test whether the risk of thrombosis increases with: 1) increasing titres of anticardiolipin antibodies (aCL) after adjustment for other car...
Gespeichert in:
| Veröffentlicht in: | Thrombosis and haemostasis 2003-07, Vol.90 (1), p.108-115 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 115 |
|---|---|
| container_issue | 1 |
| container_start_page | 108 |
| container_title | Thrombosis and haemostasis |
| container_volume | 90 |
| creator | Neville, Carolyn Rauch, Joyce Kassis, Jeannine Chang, Erika R. Joseph, Lawrence Le Comte, Martine Fortin, Paul R. |
| description | Summary
Asymptomatic antiphospholipid antibody (aPL) carriers with high risk for thrombosis may benefit from preventive anticoagulation.
It was our objective to test whether the risk of thrombosis increases with: 1) increasing titres of anticardiolipin antibodies (aCL) after adjustment for other cardiovascular risk factors and 2) the number of aPL detected.
In a cross-sectional study, blood was collected from clinics in two teaching hospitals. The study included 208 individuals suspected of having an aPL and 208 age- and sex-matched controls having blood drawn for a complete blood count.
Clinical variables included history of previous arterial (ATE) or venous (VTE) thrombotic events, traditional risk factors for cardiovascular disease, and systemic lupus erythematosus (SLE). Laboratory variables included IgG/IgM aCL, lupus anticoagulant, and IgG/IgM anti-β2-glycoprotein I.
Mean age was 46.5 years and 83% were female. Seventy-five of the 416 participants had > 1 aPL, and 69 had confirmed > 1 ATE or VTE. Family history was positive in 48% of participants, smoking in 28%, hypertension in 16%, diabetes in 6%, and SLE in 20%. A 10-unit increase in aCL IgG titre was associated with an odds ratio (OR) [95% CI] of 1.07 [1.01-1.13] for ATE and 1.06 [1.02 - 1.11] for VTE. The odds of a previous thrombosis increased with each additional aPL detected: 1.5 [0.93-2.3] for ATE and 1.7 [1.1-2.5] for VTE.
These results indicate that increased titres of aCL and multiple aPL were associated with an increased risk of a previous thrombotic event. |
| doi_str_mv | 10.1055/s-0037-1613606 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_73496895</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>73496895</sourcerecordid><originalsourceid>FETCH-LOGICAL-c604t-c7b9c94d838d50375bd9a089f9422b6f88b674b1b22fce7f555b879b89637c9f3</originalsourceid><addsrcrecordid>eNqtkr1v1jAQxiMEoi-FlRFlgS3Fib8XJFTxJVViKRKbZTtO7ZLEwee04r_HIa9aQGJjOFn2_XyP7x5X1fMWnbWI0tfQIIR507IWM8QeVIeOMt4wIb8-rA4IE9SwjtCT6gnANUItI5I-rk7aTnDGMD5U_tKnOJnoSozB1inAtzrM9aJzcHOG-jZkX_tw5esccnK1nnOwOvWh4EsB9dzX0zrmsIx7cvERSmzZ_teBiX1w8LR6NOgR3LPjelp9ef_u8vxjc_H5w6fztxeNZYjkxnIjrSS9wKKnpTNqeqmRkIMkXWfYIIRhnJjWdN1gHR8opUZwaYRkmFs54NPqzV53Wc3keluaSHpUSwqTTj9U1EH9mZmDV1fxRmEiuo6QUuDVsUCK31cHWU0BrBtHPbu4guKYyDJfWsCzHbQpAiQ33Im0SG3mKFCbOepoTrnw4ven3eNHNwrw8ghosHockp5tgHuOSESFlIVrdi774CanruOa5jLUfwvbnQfrdc56demuaN79h6JTrFReuylC1tvexjlvf0DpZH24cSoArE7B4mwog5v0vIJNYclldrwrKuE_qnBJ_lZQ4OOt8nka8U_6N_pZ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>73496895</pqid></control><display><type>article</type><title>Thromboembolic risk in patients with high titre anticardiolipin and multiple antiphospholipid antibodies</title><source>MEDLINE</source><source>Thieme Connect Journals</source><creator>Neville, Carolyn ; Rauch, Joyce ; Kassis, Jeannine ; Chang, Erika R. ; Joseph, Lawrence ; Le Comte, Martine ; Fortin, Paul R.</creator><creatorcontrib>Neville, Carolyn ; Rauch, Joyce ; Kassis, Jeannine ; Chang, Erika R. ; Joseph, Lawrence ; Le Comte, Martine ; Fortin, Paul R.</creatorcontrib><description>Summary
Asymptomatic antiphospholipid antibody (aPL) carriers with high risk for thrombosis may benefit from preventive anticoagulation.
It was our objective to test whether the risk of thrombosis increases with: 1) increasing titres of anticardiolipin antibodies (aCL) after adjustment for other cardiovascular risk factors and 2) the number of aPL detected.
In a cross-sectional study, blood was collected from clinics in two teaching hospitals. The study included 208 individuals suspected of having an aPL and 208 age- and sex-matched controls having blood drawn for a complete blood count.
Clinical variables included history of previous arterial (ATE) or venous (VTE) thrombotic events, traditional risk factors for cardiovascular disease, and systemic lupus erythematosus (SLE). Laboratory variables included IgG/IgM aCL, lupus anticoagulant, and IgG/IgM anti-β2-glycoprotein I.
Mean age was 46.5 years and 83% were female. Seventy-five of the 416 participants had > 1 aPL, and 69 had confirmed > 1 ATE or VTE. Family history was positive in 48% of participants, smoking in 28%, hypertension in 16%, diabetes in 6%, and SLE in 20%. A 10-unit increase in aCL IgG titre was associated with an odds ratio (OR) [95% CI] of 1.07 [1.01-1.13] for ATE and 1.06 [1.02 - 1.11] for VTE. The odds of a previous thrombosis increased with each additional aPL detected: 1.5 [0.93-2.3] for ATE and 1.7 [1.1-2.5] for VTE.
These results indicate that increased titres of aCL and multiple aPL were associated with an increased risk of a previous thrombotic event.</description><identifier>ISSN: 0340-6245</identifier><identifier>EISSN: 2567-689X</identifier><identifier>DOI: 10.1055/s-0037-1613606</identifier><identifier>PMID: 12876633</identifier><identifier>CODEN: THHADQ</identifier><language>eng</language><publisher>Stuttgart: Schattauer Verlag für Medizin und Naturwissenschaften</publisher><subject>Adult ; Aged ; Antibodies, Anticardiolipin - blood ; Antibodies, Antiphospholipid - blood ; Antiphospholipid Syndrome - blood ; Antiphospholipid Syndrome - complications ; Autoantigens - immunology ; Autoimmune Diseases - blood ; Autoimmune Diseases - complications ; beta 2-Glycoprotein I ; Biological and medical sciences ; Blood and lymphatic vessels ; Blood Coagulation, Fibrinolysis and Cellular Haemostasis ; Cardiology. Vascular system ; Cohort Studies ; Cross-Sectional Studies ; Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous ; Female ; General aspects ; Glycoproteins - immunology ; Humans ; Immunoglobulin G - blood ; Immunoglobulin M - blood ; Immunopathology ; Lupus Coagulation Inhibitor - blood ; Male ; Medical sciences ; Middle Aged ; Prospective Studies ; Risk ; Thromboembolism - blood ; Thromboembolism - epidemiology ; Thromboembolism - etiology ; Venous Thrombosis - blood ; Venous Thrombosis - epidemiology ; Venous Thrombosis - etiology</subject><ispartof>Thrombosis and haemostasis, 2003-07, Vol.90 (1), p.108-115</ispartof><rights>2004 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c604t-c7b9c94d838d50375bd9a089f9422b6f88b674b1b22fce7f555b879b89637c9f3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.thieme-connect.de/products/ejournals/pdf/10.1055/s-0037-1613606.pdf$$EPDF$$P50$$Gthieme$$H</linktopdf><linktohtml>$$Uhttps://www.thieme-connect.de/products/ejournals/html/10.1055/s-0037-1613606$$EHTML$$P50$$Gthieme$$H</linktohtml><link.rule.ids>230,314,776,780,881,3003,3004,27903,27904,54537,54538</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14905899$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12876633$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Neville, Carolyn</creatorcontrib><creatorcontrib>Rauch, Joyce</creatorcontrib><creatorcontrib>Kassis, Jeannine</creatorcontrib><creatorcontrib>Chang, Erika R.</creatorcontrib><creatorcontrib>Joseph, Lawrence</creatorcontrib><creatorcontrib>Le Comte, Martine</creatorcontrib><creatorcontrib>Fortin, Paul R.</creatorcontrib><title>Thromboembolic risk in patients with high titre anticardiolipin and multiple antiphospholipid antibodies</title><title>Thrombosis and haemostasis</title><addtitle>Thromb Haemost</addtitle><description>Summary
Asymptomatic antiphospholipid antibody (aPL) carriers with high risk for thrombosis may benefit from preventive anticoagulation.
It was our objective to test whether the risk of thrombosis increases with: 1) increasing titres of anticardiolipin antibodies (aCL) after adjustment for other cardiovascular risk factors and 2) the number of aPL detected.
In a cross-sectional study, blood was collected from clinics in two teaching hospitals. The study included 208 individuals suspected of having an aPL and 208 age- and sex-matched controls having blood drawn for a complete blood count.
Clinical variables included history of previous arterial (ATE) or venous (VTE) thrombotic events, traditional risk factors for cardiovascular disease, and systemic lupus erythematosus (SLE). Laboratory variables included IgG/IgM aCL, lupus anticoagulant, and IgG/IgM anti-β2-glycoprotein I.
Mean age was 46.5 years and 83% were female. Seventy-five of the 416 participants had > 1 aPL, and 69 had confirmed > 1 ATE or VTE. Family history was positive in 48% of participants, smoking in 28%, hypertension in 16%, diabetes in 6%, and SLE in 20%. A 10-unit increase in aCL IgG titre was associated with an odds ratio (OR) [95% CI] of 1.07 [1.01-1.13] for ATE and 1.06 [1.02 - 1.11] for VTE. The odds of a previous thrombosis increased with each additional aPL detected: 1.5 [0.93-2.3] for ATE and 1.7 [1.1-2.5] for VTE.
These results indicate that increased titres of aCL and multiple aPL were associated with an increased risk of a previous thrombotic event.</description><subject>Adult</subject><subject>Aged</subject><subject>Antibodies, Anticardiolipin - blood</subject><subject>Antibodies, Antiphospholipid - blood</subject><subject>Antiphospholipid Syndrome - blood</subject><subject>Antiphospholipid Syndrome - complications</subject><subject>Autoantigens - immunology</subject><subject>Autoimmune Diseases - blood</subject><subject>Autoimmune Diseases - complications</subject><subject>beta 2-Glycoprotein I</subject><subject>Biological and medical sciences</subject><subject>Blood and lymphatic vessels</subject><subject>Blood Coagulation, Fibrinolysis and Cellular Haemostasis</subject><subject>Cardiology. Vascular system</subject><subject>Cohort Studies</subject><subject>Cross-Sectional Studies</subject><subject>Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous</subject><subject>Female</subject><subject>General aspects</subject><subject>Glycoproteins - immunology</subject><subject>Humans</subject><subject>Immunoglobulin G - blood</subject><subject>Immunoglobulin M - blood</subject><subject>Immunopathology</subject><subject>Lupus Coagulation Inhibitor - blood</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Prospective Studies</subject><subject>Risk</subject><subject>Thromboembolism - blood</subject><subject>Thromboembolism - epidemiology</subject><subject>Thromboembolism - etiology</subject><subject>Venous Thrombosis - blood</subject><subject>Venous Thrombosis - epidemiology</subject><subject>Venous Thrombosis - etiology</subject><issn>0340-6245</issn><issn>2567-689X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqtkr1v1jAQxiMEoi-FlRFlgS3Fib8XJFTxJVViKRKbZTtO7ZLEwee04r_HIa9aQGJjOFn2_XyP7x5X1fMWnbWI0tfQIIR507IWM8QeVIeOMt4wIb8-rA4IE9SwjtCT6gnANUItI5I-rk7aTnDGMD5U_tKnOJnoSozB1inAtzrM9aJzcHOG-jZkX_tw5esccnK1nnOwOvWh4EsB9dzX0zrmsIx7cvERSmzZ_teBiX1w8LR6NOgR3LPjelp9ef_u8vxjc_H5w6fztxeNZYjkxnIjrSS9wKKnpTNqeqmRkIMkXWfYIIRhnJjWdN1gHR8opUZwaYRkmFs54NPqzV53Wc3keluaSHpUSwqTTj9U1EH9mZmDV1fxRmEiuo6QUuDVsUCK31cHWU0BrBtHPbu4guKYyDJfWsCzHbQpAiQ33Im0SG3mKFCbOepoTrnw4ven3eNHNwrw8ghosHockp5tgHuOSESFlIVrdi774CanruOa5jLUfwvbnQfrdc56demuaN79h6JTrFReuylC1tvexjlvf0DpZH24cSoArE7B4mwog5v0vIJNYclldrwrKuE_qnBJ_lZQ4OOt8nka8U_6N_pZ</recordid><startdate>20030701</startdate><enddate>20030701</enddate><creator>Neville, Carolyn</creator><creator>Rauch, Joyce</creator><creator>Kassis, Jeannine</creator><creator>Chang, Erika R.</creator><creator>Joseph, Lawrence</creator><creator>Le Comte, Martine</creator><creator>Fortin, Paul R.</creator><general>Schattauer Verlag für Medizin und Naturwissenschaften</general><general>Schattauer GmbH</general><general>Schattauer</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20030701</creationdate><title>Thromboembolic risk in patients with high titre anticardiolipin and multiple antiphospholipid antibodies</title><author>Neville, Carolyn ; Rauch, Joyce ; Kassis, Jeannine ; Chang, Erika R. ; Joseph, Lawrence ; Le Comte, Martine ; Fortin, Paul R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c604t-c7b9c94d838d50375bd9a089f9422b6f88b674b1b22fce7f555b879b89637c9f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antibodies, Anticardiolipin - blood</topic><topic>Antibodies, Antiphospholipid - blood</topic><topic>Antiphospholipid Syndrome - blood</topic><topic>Antiphospholipid Syndrome - complications</topic><topic>Autoantigens - immunology</topic><topic>Autoimmune Diseases - blood</topic><topic>Autoimmune Diseases - complications</topic><topic>beta 2-Glycoprotein I</topic><topic>Biological and medical sciences</topic><topic>Blood and lymphatic vessels</topic><topic>Blood Coagulation, Fibrinolysis and Cellular Haemostasis</topic><topic>Cardiology. Vascular system</topic><topic>Cohort Studies</topic><topic>Cross-Sectional Studies</topic><topic>Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous</topic><topic>Female</topic><topic>General aspects</topic><topic>Glycoproteins - immunology</topic><topic>Humans</topic><topic>Immunoglobulin G - blood</topic><topic>Immunoglobulin M - blood</topic><topic>Immunopathology</topic><topic>Lupus Coagulation Inhibitor - blood</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Prospective Studies</topic><topic>Risk</topic><topic>Thromboembolism - blood</topic><topic>Thromboembolism - epidemiology</topic><topic>Thromboembolism - etiology</topic><topic>Venous Thrombosis - blood</topic><topic>Venous Thrombosis - epidemiology</topic><topic>Venous Thrombosis - etiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Neville, Carolyn</creatorcontrib><creatorcontrib>Rauch, Joyce</creatorcontrib><creatorcontrib>Kassis, Jeannine</creatorcontrib><creatorcontrib>Chang, Erika R.</creatorcontrib><creatorcontrib>Joseph, Lawrence</creatorcontrib><creatorcontrib>Le Comte, Martine</creatorcontrib><creatorcontrib>Fortin, Paul R.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Thrombosis and haemostasis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Neville, Carolyn</au><au>Rauch, Joyce</au><au>Kassis, Jeannine</au><au>Chang, Erika R.</au><au>Joseph, Lawrence</au><au>Le Comte, Martine</au><au>Fortin, Paul R.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Thromboembolic risk in patients with high titre anticardiolipin and multiple antiphospholipid antibodies</atitle><jtitle>Thrombosis and haemostasis</jtitle><addtitle>Thromb Haemost</addtitle><date>2003-07-01</date><risdate>2003</risdate><volume>90</volume><issue>1</issue><spage>108</spage><epage>115</epage><pages>108-115</pages><issn>0340-6245</issn><eissn>2567-689X</eissn><coden>THHADQ</coden><abstract>Summary
Asymptomatic antiphospholipid antibody (aPL) carriers with high risk for thrombosis may benefit from preventive anticoagulation.
It was our objective to test whether the risk of thrombosis increases with: 1) increasing titres of anticardiolipin antibodies (aCL) after adjustment for other cardiovascular risk factors and 2) the number of aPL detected.
In a cross-sectional study, blood was collected from clinics in two teaching hospitals. The study included 208 individuals suspected of having an aPL and 208 age- and sex-matched controls having blood drawn for a complete blood count.
Clinical variables included history of previous arterial (ATE) or venous (VTE) thrombotic events, traditional risk factors for cardiovascular disease, and systemic lupus erythematosus (SLE). Laboratory variables included IgG/IgM aCL, lupus anticoagulant, and IgG/IgM anti-β2-glycoprotein I.
Mean age was 46.5 years and 83% were female. Seventy-five of the 416 participants had > 1 aPL, and 69 had confirmed > 1 ATE or VTE. Family history was positive in 48% of participants, smoking in 28%, hypertension in 16%, diabetes in 6%, and SLE in 20%. A 10-unit increase in aCL IgG titre was associated with an odds ratio (OR) [95% CI] of 1.07 [1.01-1.13] for ATE and 1.06 [1.02 - 1.11] for VTE. The odds of a previous thrombosis increased with each additional aPL detected: 1.5 [0.93-2.3] for ATE and 1.7 [1.1-2.5] for VTE.
These results indicate that increased titres of aCL and multiple aPL were associated with an increased risk of a previous thrombotic event.</abstract><cop>Stuttgart</cop><pub>Schattauer Verlag für Medizin und Naturwissenschaften</pub><pmid>12876633</pmid><doi>10.1055/s-0037-1613606</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0340-6245 |
| ispartof | Thrombosis and haemostasis, 2003-07, Vol.90 (1), p.108-115 |
| issn | 0340-6245 2567-689X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_73496895 |
| source | MEDLINE; Thieme Connect Journals |
| subjects | Adult Aged Antibodies, Anticardiolipin - blood Antibodies, Antiphospholipid - blood Antiphospholipid Syndrome - blood Antiphospholipid Syndrome - complications Autoantigens - immunology Autoimmune Diseases - blood Autoimmune Diseases - complications beta 2-Glycoprotein I Biological and medical sciences Blood and lymphatic vessels Blood Coagulation, Fibrinolysis and Cellular Haemostasis Cardiology. Vascular system Cohort Studies Cross-Sectional Studies Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous Female General aspects Glycoproteins - immunology Humans Immunoglobulin G - blood Immunoglobulin M - blood Immunopathology Lupus Coagulation Inhibitor - blood Male Medical sciences Middle Aged Prospective Studies Risk Thromboembolism - blood Thromboembolism - epidemiology Thromboembolism - etiology Venous Thrombosis - blood Venous Thrombosis - epidemiology Venous Thrombosis - etiology |
| title | Thromboembolic risk in patients with high titre anticardiolipin and multiple antiphospholipid antibodies |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T23%3A54%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Thromboembolic%20risk%20in%20patients%20with%20high%20titre%20anticardiolipin%20and%20multiple%20antiphospholipid%20antibodies&rft.jtitle=Thrombosis%20and%20haemostasis&rft.au=Neville,%20Carolyn&rft.date=2003-07-01&rft.volume=90&rft.issue=1&rft.spage=108&rft.epage=115&rft.pages=108-115&rft.issn=0340-6245&rft.eissn=2567-689X&rft.coden=THHADQ&rft_id=info:doi/10.1055/s-0037-1613606&rft_dat=%3Cproquest_cross%3E73496895%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=73496895&rft_id=info:pmid/12876633&rfr_iscdi=true |